NEXUS AG: CONTINUED SALES AND OPERATING RESULT INCREASE IN THE FIRST QUARTER 2019

Donaueschingen, 3 May 2019: Nexus AG, specialized in hospital software, was able to increase sales by approx. 11 % and its Group result for earnings before interest and taxes by approx. 18 % in the first quarter 2019. As a result, the long-term growth course of the NEXUS Group could be continued.

Sales increased by approx. 10.7 % from KEUR 32,044 (Q1 2018) to KEUR 35,465 in the first quarter 2019.

The Group result for earnings before interest and taxes (EBIT) improved by 17.9 % to KEUR 3,882 (Q1 2018: KEUR 3,293). A value of KEUR 4,772 could be achieved in EBITA. Consequently, it was 18.7 % above the previous year's value (Q1 2018: KEUR 4,021). EBITDA in the first quarter of 2019 was KEUR 7,548 (adjusted for IFRS 16 effect: KEUR 6,755) and consequently 30.3 % (adjusted for IFRS 16 effect:



16.6 %) above the previous year (Q1 2018: KEUR 5,792). The consolidated surplus amounted to KEUR 2,855 for the first quarter 2019 following KEUR 2,511 (Q1 2018).

Development of Group Earnings before Interest and Taxes (3 months) KEUR



The cash flow from operating activities reached KEUR 26,233 following KEUR 17,285 (Q1 2018) in the previous year. NEXUS AG had cash funds incl. short-term financial assets amounting to KEUR 51,444 as of 31 March 2019 (31 March 2018: KEUR 38,559).

The undiluted earnings per share amounted to EUR 0.18 (previous year: EUR 0.17) (diluted: EUR 0.18; previous year: EUR 0.17).

NEXUS AG has equity capital amounting to KEUR 110,714 (31 December 2018: KEUR 108,325). This demonstrates that

NEXUS AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy.

The detailed Quarterly Report can be found on our homepage at: <u>https://en-en.nexus-ag.de/company/investor-relations</u> – Financial Reports

ABOUT NEXUS AG

NEXUS AG is a software vendor specialized in eHealth solutions. NEXUS software helps hospitals, psychiatric and rehabilitation clinics to increase efficiency and safety in treating patients. More than 1,280 staff members at NEXUS develop solutions for approx. 270,000 users in 25 countries.

